Catalyst Pharmaceuticals (CPRX) EBIAT: 2010-2025
Historic EBIAT for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.
- Catalyst Pharmaceuticals' EBIAT rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 52.36%. This contributed to the annual value of $163.9 million for FY2024, which is 129.50% up from last year.
- As of Q3 2025, Catalyst Pharmaceuticals' EBIAT stood at $52.8 million, which was up 1.30% from $52.1 million recorded in Q2 2025.
- Over the past 5 years, Catalyst Pharmaceuticals' EBIAT peaked at $56.7 million during Q1 2025, and registered a low of -$30.8 million during Q3 2023.
- Over the past 3 years, Catalyst Pharmaceuticals' median EBIAT value was $40.8 million (recorded in 2024), while the average stood at $36.1 million.
- As far as peak fluctuations go, Catalyst Pharmaceuticals' EBIAT crashed by 235.24% in 2023, and later surged by 242.65% in 2024.
- Catalyst Pharmaceuticals' EBIAT (Quarterly) stood at $9.3 million in 2021, then spiked by 173.62% to $25.5 million in 2022, then spiked by 36.80% to $34.8 million in 2023, then spiked by 60.53% to $55.9 million in 2024, then increased by 20.28% to $52.8 million in 2025.
- Its EBIAT stands at $52.8 million for Q3 2025, versus $52.1 million for Q2 2025 and $56.7 million for Q1 2025.